JPWO2022031978A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022031978A5 JPWO2022031978A5 JP2023507563A JP2023507563A JPWO2022031978A5 JP WO2022031978 A5 JPWO2022031978 A5 JP WO2022031978A5 JP 2023507563 A JP2023507563 A JP 2023507563A JP 2023507563 A JP2023507563 A JP 2023507563A JP WO2022031978 A5 JPWO2022031978 A5 JP WO2022031978A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- pharmaceutical composition
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063062243P | 2020-08-06 | 2020-08-06 | |
| US63/062,243 | 2020-08-06 | ||
| PCT/US2021/044761 WO2022031978A1 (en) | 2020-08-06 | 2021-08-05 | Inflammatory cytokines and fatigue in subject with a complement mediated disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023536904A JP2023536904A (ja) | 2023-08-30 |
| JP2023536904A5 JP2023536904A5 (https=) | 2024-12-16 |
| JPWO2022031978A5 true JPWO2022031978A5 (https=) | 2024-12-16 |
Family
ID=77750323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507563A Pending JP2023536904A (ja) | 2020-08-06 | 2021-08-05 | 補体が媒介する疾患を有する対象における炎症性サイトカインおよび疲労 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230357433A1 (https=) |
| EP (1) | EP4193153A1 (https=) |
| JP (1) | JP2023536904A (https=) |
| KR (1) | KR20230044312A (https=) |
| CN (1) | CN116724236A (https=) |
| AU (1) | AU2021320870A1 (https=) |
| BR (1) | BR112023001942A2 (https=) |
| CA (1) | CA3187866A1 (https=) |
| IL (1) | IL300376A (https=) |
| MX (1) | MX2023001492A (https=) |
| WO (1) | WO2022031978A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104870475B (zh) | 2012-10-25 | 2019-11-08 | 美国比奥维拉迪维股份有限公司 | 抗补体C1s抗体和其用途 |
| DK2914291T3 (da) | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
| HUE073475T2 (hu) | 2016-10-12 | 2026-01-28 | Bioverativ Usa Inc | C1s elleni antitestek és alkalmazási eljárásaik |
| CN117241828A (zh) * | 2021-03-31 | 2023-12-15 | 美国比奥维拉迪维股份有限公司 | 减少冷凝集素病患者的手术相关溶血 |
| US20240117021A1 (en) * | 2022-06-15 | 2024-04-11 | Bioverativ Usa Inc. | Anti-complement c1s antibody formulation |
| IL317947A (en) * | 2022-06-24 | 2025-02-01 | Bioverativ Usa Inc | Complementary disease treatment methods |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
| GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
| WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| ES2776406T3 (es) | 2007-07-12 | 2020-07-30 | Gitr Inc | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
| DK2914291T3 (da) | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
| EP2996722A4 (en) * | 2013-05-15 | 2017-01-11 | Annexon, Inc. | Methods of treatment for guillain-barre syndrome |
| WO2016164358A1 (en) | 2015-04-06 | 2016-10-13 | True North Therapeutics, Inc. | Humanized anti-c1s antibodies and methods of use thereof |
| US20180169240A1 (en) * | 2015-06-26 | 2018-06-21 | Bioverativ Usa Inc. | Methods of treating autoimmune and alloimmune disorders |
| ES3062420T3 (en) * | 2016-08-25 | 2026-04-10 | California Inst Of Techn | Ascaroside treatment of eosinophilic esophagitis |
| HUE073475T2 (hu) * | 2016-10-12 | 2026-01-28 | Bioverativ Usa Inc | C1s elleni antitestek és alkalmazási eljárásaik |
| CA3055781A1 (en) | 2017-03-14 | 2018-09-20 | Bioverativ Usa Inc. | Methods for treating complement-mediated diseases and disorders |
| CR20200542A (es) * | 2018-04-13 | 2021-01-18 | Chugaiseiyaku Kk | Anticuerpos anti-componente de complemento y métodos de uso |
| CA3118453A1 (en) * | 2018-11-02 | 2020-05-07 | The Regents Of The University Of California | Compositions and methods for treating brain injury |
-
2021
- 2021-08-05 IL IL300376A patent/IL300376A/en unknown
- 2021-08-05 EP EP21770091.3A patent/EP4193153A1/en active Pending
- 2021-08-05 MX MX2023001492A patent/MX2023001492A/es unknown
- 2021-08-05 WO PCT/US2021/044761 patent/WO2022031978A1/en not_active Ceased
- 2021-08-05 KR KR1020237007908A patent/KR20230044312A/ko active Pending
- 2021-08-05 CN CN202180056699.1A patent/CN116724236A/zh active Pending
- 2021-08-05 JP JP2023507563A patent/JP2023536904A/ja active Pending
- 2021-08-05 BR BR112023001942A patent/BR112023001942A2/pt unknown
- 2021-08-05 AU AU2021320870A patent/AU2021320870A1/en active Pending
- 2021-08-05 CA CA3187866A patent/CA3187866A1/en active Pending
-
2023
- 2023-02-03 US US18/164,521 patent/US20230357433A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6189980B2 (ja) | Ｉｌ−１結合タンパク質 | |
| TWI688404B (zh) | 抗-催乳素受體抗體調配物 | |
| CN108404127B (zh) | 恶病质治疗 | |
| JP2020522261A5 (https=) | ||
| JP7288927B2 (ja) | 乾癬性関節炎患者における構造的損傷の進行を阻害するためのｉｌ－１７アンタゴニストの使用 | |
| HK1215265A1 (en) | Treatment of tnf alpha related disorders | |
| US11059906B2 (en) | Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma | |
| JP2014509510A5 (https=) | ||
| JPWO2018191479A5 (https=) | ||
| CN116474091A (zh) | 生物医药组合物 | |
| KR20210071944A (ko) | 인플라마솜 관련 질환 또는 상태 치료용 조성물 및 방법 | |
| CN116745315A (zh) | 用于治疗嗜中性皮肤病的抗il-36r抗体 | |
| JPWO2022031978A5 (https=) | ||
| JP2017530089A (ja) | 抗ｉｌ４−ｉｌ１３二重特異性抗体 | |
| CN111344043A (zh) | 使用白细胞介素-17(il-17)拮抗剂治疗肌腱病的方法 | |
| JP2014515743A (ja) | Ｔｇｆ−アルファおよびエピレグリンに結合する抗体 | |
| RU2023104423A (ru) | Воспалительные цитокины и утомляемость у субъекта с опосредованным комплементом заболеванием | |
| JP7610767B2 (ja) | レット症候群の処置のためのセマフォリン４ｄ結合分子の使用 | |
| JPWO2019171252A5 (https=) | ||
| TWI737000B (zh) | 用於治療化膿性汗腺炎之泛-ｅｌｒ＋ｃｘｃ趨化介素抗體 | |
| BR112019023141A2 (pt) | métodos de tratamento seletivo da asma usando antagonistas de il-17 | |
| JPWO2020218232A5 (https=) | ||
| JP2024510923A (ja) | 汎発性膿疱性乾癬を処置する方法 | |
| WO2013177264A1 (en) | Anti-ccl2 antibodies for treatment of scleroderma | |
| RU2021104860A (ru) | Антитела против CXCR2 и их применение |